Misplaced Pages

Botaretigene sparoparvovec

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Experimental gene therapy
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2023)

Botaretigene sparoparvovec (AAV5-RPGR) is an experimental gene therapy for X-linked retinitis pigmentosa developed by Janssen Pharmaceuticals.

References

  1. Michaelides, Michel; Xu, Jialin; Wang, Dai; Wong, Peggy; Fung, Albert; Forbes, Alexandra; Naylor, Stuart; Zeldin, Robert; Parker, Maria A; Weleber, Richard; Guimaraes, Thales Antonio Cabral de; Besirli, Cagri; Yang, Yesa; Bainbridge, James (2022-06-01). "AAV5-RPGR (botaretigene sparoparvovec) gene therapy for X-linked retinitis pigmentosa (XLRP) demonstrates localized improvements in static perimetry". Investigative Ophthalmology & Visual Science. 63 (7). The Association for Research in Vision and Ophthalmology: 3846. ISSN 1552-5783. Retrieved 2023-12-05.
  2. "Humoral immune response to AAV5-RPGR (botaretigene sparoparvovec) gene therapy in RPGR-associated X-linked retinitis pigmentosa". Investigative Ophthalmology & Visual Science.
Categories: